Mod-GRF 1-29
Also known as: CJC-1295 no DAC, CJC-1295 without DAC, Modified GRF, Modified GRF 1-29, Sermorelin analog, Tesamorelin analog
Source Mod-GRF 1-29 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Modified growth hormone-releasing factor (1-29) with enhanced stability and bioactivity; truncated GHRH analog used in research settings for growth hormone stimulation
Mechanism of Action
Selective GHRH receptor agonist stimulating pulsatile growth hormone release from anterior pituitary
Routes of Administration
Goals & Uses
- fat lossBody CompositionLow
- anti-agingLongevityLow
- Growth hormone deficiencyEndocrineModerate
- Body composition improvementMetabolicLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- hypersensitivity to GHRH analogsImmunologicHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- diabetes mellitusMetabolicModerate
Adverse Effects
- HypoglycemiaMetabolicRareAbnormally low blood glucose
- Carpal tunnel syndromeMusculoskeletalRare
- HeadacheNeurologicUncommonPain in the head or upper neck
- Antibody FormationImmunologicalRare
- fluid retentionMetabolicUncommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
Drug Interactions
- GlucocorticoidsModerate
- IGF-1Low
- insulin/oral hypoglycemicsModerate
- somatostatin analogsModerate
Population Constraints
- patients with intracranial lesionsNeurologicAbsolute
- Pediatric patientsAgeRelative
- patients with diabetic retinopathyOphthalmologicRelative
- Elderly patientsAgeRelative
- Patients with history of cancerOncologyRelative
Regulatory Status
- European UnionUnapprovedNot EMA approved; regulated as research chemical
- United StatesUnapprovedNot FDA approved; DEA Schedule III controlled substance in some states; research use only
- United KingdomUnapprovedNot MHRA approved; controlled under Psychoactive Substances Act in some contexts
Not approved for human therapeutic use; available as research chemical; regulatory status varies by jurisdiction
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Mod-GRF 1-29?
Modified growth hormone-releasing factor (1-29) with enhanced stability and bioactivity; truncated GHRH analog used in research settings for growth hormone stimulation
What is Mod-GRF 1-29 used for?
Mod-GRF 1-29 is educationally associated with: fat loss, anti-aging, Growth hormone deficiency, Body composition improvement. Educational only — not medical advice.
How is Mod-GRF 1-29 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Mod-GRF 1-29?
Reported adverse effects include: Hypoglycemia, Carpal tunnel syndrome, Headache, Antibody Formation, fluid retention, Injection site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Mod-GRF 1-29?
Recorded contraindications: Active malignancy, hypersensitivity to GHRH analogs, Pregnancy, diabetes mellitus. Consult a qualified clinician before use.